Get the Stockscreener App
22.26
1.04%
0.23
After Hours:
22.26
Overview
News
Price History
Option Chain
Why FMS Down?
Discussions
Forecast
Stock Split
Dividend History
Fresenius Medical Care Ag Adr stock is traded at $22.26, with a volume of 361.08K.
It is up +1.04% in the last 24 hours and down -1.72% over the past month.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
See More
Previous Close:
$22.03
Open:
$22.3
24h Volume:
361.08K
Relative Volume:
0.60
Market Cap:
$12.43B
Revenue:
$22.18B
Net Income/Loss:
$1.36B
P/E Ratio:
11.58
EPS:
1.9216
Net Cash Flow:
$2.00B
1W Performance:
-0.67%
1M Performance:
-1.72%
6M Performance:
-11.67%
1Y Performance:
-8.96%
1-Day Range:
$21.99
$22.31
1-Week Range:
$21.56
$22.45
52-Week Range:
$20.95
$30.46
Fresenius Medical Care Ag Adr Stock (FMS) Company Profile
Name
Fresenius Medical Care Ag Adr
Sector
Industry
Phone
-
Address
-
Compare FMS vs HCA, THC, ENSG, UHS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FMS
Fresenius Medical Care Ag Adr
|
22.26 | 12.31B | 22.18B | 1.36B | 2.00B | 1.9216 |
HCA
Hca Healthcare Inc
|
484.02 | 108.59B | 75.60B | 7.78B | 7.69B | 28.38 |
THC
Tenet Healthcare Corp
|
200.04 | 17.36B | 21.31B | 2.37B | 2.53B | 15.49 |
ENSG
Ensign Group Inc
|
203.89 | 11.79B | 5.06B | 344.26M | 370.71M | 5.8446 |
UHS
Universal Health Services Inc
|
186.72 | 11.36B | 17.36B | 1.51B | 849.25M | 23.15 |
Fresenius Medical Care Ag Adr Stock (FMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Goldman | Buy → Neutral |
| Oct-15-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-02-25 | Downgrade | UBS | Neutral → Sell |
| Dec-02-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-06-24 | Initiated | Berenberg | Buy |
| Jan-08-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-24-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-17-23 | Upgrade | Societe Generale | Hold → Buy |
| Aug-14-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Resumed | Citigroup | Neutral |
| Jul-12-23 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | Bernstein | Mkt Perform |
| Jan-03-23 | Downgrade | Jefferies | Buy → Underperform |
| Oct-26-22 | Downgrade | Deutsche Bank | Hold → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-27-22 | Upgrade | Jefferies | Underperform → Buy |
| Feb-11-22 | Downgrade | Jefferies | Hold → Underperform |
| Nov-23-21 | Initiated | HSBC Securities | Hold |
| Nov-11-21 | Upgrade | Jefferies | Underperform → Hold |
| Feb-04-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-03-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| May-20-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-21-20 | Upgrade | Jefferies | Hold → Buy |
| Jun-20-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-26-18 | Upgrade | UBS | Neutral → Buy |
| Aug-28-18 | Upgrade | HSBC Securities | Hold → Buy |
| Jul-05-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-04-18 | Upgrade | UBS | Sell → Neutral |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-01-16 | Reiterated | RBC Capital Mkts | Sector Perform |
| Sep-06-16 | Upgrade | Citigroup | Neutral → Buy |
| Jul-08-16 | Upgrade | Jefferies | Underperform → Hold |
| Jan-04-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-04-15 | Reiterated | RBC Capital Mkts | Sector Perform |
| Sep-03-15 | Upgrade | Goldman | Neutral → Buy |
| Aug-13-15 | Downgrade | Societe Generale | Buy → Hold |
| Jul-31-15 | Reiterated | RBC Capital Mkts | Sector Perform |
| Aug-02-13 | Reiterated | Feltl & Co. | Hold |
| Jan-14-13 | Upgrade | HSBC Securities | Neutral → Overweight |
View All
Fresenius Medical Care Ag Adr Stock (FMS) Latest News
Fresenius Medical Care stock advances FME Reignite strategy with Interwell Health investment amid st - AD HOC NEWS
10 New 5-Star Stocks This Week - Morningstar
Fresenius Medical Care publishes its Annual Report 2025: The power of care - Fresenius Medical Care
Research in brief: Population Characteristics in Randomized Clinical Trials for Hemodiafiltration - Fresenius Medical Care
Advancing kidney care: Introducing high-volume hemodiafiltration to the U.S. - Fresenius Medical Care
Fresenius Medical Care Faces a Transition Year in 2026 on New Product Launch Activities - Morningstar
Fresenius Medical Care marks World Kidney Day and National Kidney Month - Fresenius Medical Care
Fresenius Medical Care's 2030 Ambition: Navigating a Pivotal Transition () - aktiencheck.de
Fresenius Medical Care: An Undervalued Stock to Buy Now and Hold for the Long Term - Morningstar
5 Undervalued Stocks That Crushed Q4 Earnings - Morningstar
FMS Stock Rises as Q4 Earnings & Sales Beat Estimates, Margins Expand - Finviz
Research in brief: Nocturnal home hemodialysis - Fresenius Medical Care
Fresenius Medical Care ADR earnings beat by $1.11, revenue topped estimates - Investing.com Australia
Fresenius Medical Care published Report on Form 20-F for fiscal year 2025 - Fresenius Medical Care
Fresenius Medical Care Q4 2025 slides: margin surge, flat 2026 outlook - Investing.com
Earnings call transcript: Fresenius Medical Care Q4 2025 beats EPS expectations - Investing.com
Fresenius Medical Care falls nearly 7% despite earnings beat - Investing.com South Africa
Fresenius Medical Care falls 7% after 2026 flat growth outlook and cost update - Investing.com
Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band - Fresenius Medical Care
Uncovering Potential: Fresenius Medical Care's Earnings Preview - Sahm
Research in Brief: Hemodiafiltration and hospitalization burden in ESKD - Fresenius Medical Care
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Allstate Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Statement from Fresenius Medical Care on Upcoming Winter Storm - Fresenius Medical Care
Annual Press Conference 2026 - Fresenius Medical Care
18 of the Best Stocks and ETFs to Buy Based on 2026 Expert Forecasts - Morningstar
6 New 5-Star Stocks - Morningstar
Research in brief: Implementation of Online High-Volume Hemodiafiltration - Fresenius Medical Care
Goldman Sachs downgrades Fresenius Medical Care stock on 2026 headwinds By Investing.com - Investing.com South Africa
Goldman Sachs downgrades Fresenius Medical Care stock on 2026 headwinds - Investing.com
Reasons to Add Fresenius Medical Stock to Your Portfolio Now - Finviz
Fresenius Medical Care accelerates second tranche of share buyback - Investing.com
Fresenius Medical Care accelerates second tranche of share buyback By Investing.com - Investing.com India
Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned - Fresenius Medical Care
Finding purpose and perseverance: A dialysis nurse’s quiet heroism - Fresenius Medical Care
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now - Finviz
Fresenius Medical Care names Charles Hugh-Jones as new global CMO By Investing.com - Investing.com South Africa
Fresenius Medical Care names Charles Hugh-Jones as new global CMO - Investing.com India
Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board - Fresenius Medical Care
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Research in brief: Time on treatment - Fresenius Medical Care
Alphabet Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Fresenius Medical Care Ag Adr Stock (FMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):